CN102256977B - 嘌呤化合物 - Google Patents

嘌呤化合物 Download PDF

Info

Publication number
CN102256977B
CN102256977B CN200980150689.3A CN200980150689A CN102256977B CN 102256977 B CN102256977 B CN 102256977B CN 200980150689 A CN200980150689 A CN 200980150689A CN 102256977 B CN102256977 B CN 102256977B
Authority
CN
China
Prior art keywords
methyl
tetrahydro
pharmaceutically acceptable
purine
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200980150689.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN102256977A (zh
Inventor
P·C·阿瑟尔斯
R·圭代蒂
S·P·霍林斯黑德
M·W·蒂德维尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN102256977A publication Critical patent/CN102256977A/zh
Application granted granted Critical
Publication of CN102256977B publication Critical patent/CN102256977B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN200980150689.3A 2008-12-18 2009-12-09 嘌呤化合物 Expired - Fee Related CN102256977B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13858908P 2008-12-18 2008-12-18
US61/138,589 2008-12-18
PCT/US2009/067249 WO2010080306A1 (en) 2008-12-18 2009-12-09 Purine compounds

Publications (2)

Publication Number Publication Date
CN102256977A CN102256977A (zh) 2011-11-23
CN102256977B true CN102256977B (zh) 2014-04-16

Family

ID=41719189

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980150689.3A Expired - Fee Related CN102256977B (zh) 2008-12-18 2009-12-09 嘌呤化合物

Country Status (29)

Country Link
US (1) US8252798B2 (enExample)
EP (1) EP2379555B1 (enExample)
JP (1) JP5559812B2 (enExample)
KR (1) KR101319630B1 (enExample)
CN (1) CN102256977B (enExample)
AR (1) AR075104A1 (enExample)
AU (1) AU2009335997B2 (enExample)
BR (1) BRPI0923195A2 (enExample)
CA (1) CA2746740C (enExample)
CL (1) CL2011001464A1 (enExample)
CO (1) CO6390101A2 (enExample)
CR (1) CR20110340A (enExample)
DO (1) DOP2011000196A (enExample)
EA (1) EA018386B1 (enExample)
EC (1) ECSP11011151A (enExample)
ES (1) ES2536880T3 (enExample)
HN (1) HN2011001700A (enExample)
IL (1) IL213167A (enExample)
MA (1) MA32904B1 (enExample)
MX (1) MX2011006442A (enExample)
NZ (1) NZ593088A (enExample)
PA (1) PA8851501A1 (enExample)
PE (1) PE20110999A1 (enExample)
SG (1) SG172253A1 (enExample)
TN (1) TN2011000291A1 (enExample)
TW (1) TWI376378B (enExample)
UA (1) UA104010C2 (enExample)
WO (1) WO2010080306A1 (enExample)
ZA (1) ZA201103943B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010103130A2 (en) * 2009-03-13 2010-09-16 Katholieke Universiteit Leuven, K.U.Leuven R&D Novel bicyclic heterocycles
SG10201404925TA (en) 2009-08-28 2014-10-30 Arena Pharm Inc Cannabinoid receptor modulators
CN102869359A (zh) * 2010-03-17 2013-01-09 弗·哈夫曼-拉罗切有限公司 咪唑并吡啶和嘌呤化合物、组合物和使用方法
AR080711A1 (es) 2010-03-31 2012-05-02 Lilly Co Eli Compuesto de piperazin-purina composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento o prevencion del dolor
KR101432411B1 (ko) * 2010-03-31 2014-08-20 일라이 릴리 앤드 캄파니 Ｃｂ2 효능제로서 사용되는 퓨린 화합물
BR112013006016A2 (pt) 2010-09-15 2016-06-07 Hoffmann La Roche compostos de azabenzotiazol, composições e métodos de uso
WO2012066061A1 (en) 2010-11-19 2012-05-24 F. Hoffmann-La Roche Ag Pyrazolopyridines and pyrazolopyridines and their use as tyk2 inhibitors
CN103492369B (zh) 2011-02-25 2019-03-29 艾尼纳制药公司 大麻素受体调节剂
WO2012116277A1 (en) 2011-02-25 2012-08-30 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
EP3395812B8 (en) 2011-02-25 2022-11-02 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of condensed azacycles (cannabinoid receptor modulators)
HK1198365A1 (en) * 2011-09-20 2015-04-10 F. Hoffmann-La Roche Ag Imidazopyridine compounds, compositions and methods of use
US9067943B2 (en) * 2011-11-25 2015-06-30 Hoffmann-La Roche Inc. [1,2,3]triazolo[4,5-D]pyrimidine derivatives
PE20151140A1 (es) * 2012-08-16 2015-08-07 Janssen Pharmaceutica Nv Pirazoles sustituidos como bloqueadores del canal de calcio tipo n
EP2951180B1 (en) 2013-01-30 2018-05-02 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
KR20160002857A (ko) * 2013-05-02 2016-01-08 에프. 호프만-라 로슈 아게 CB2 수용체 작용제로서의 피롤로[2,3-d]피리미딘 유도체
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
WO2017052394A1 (en) * 2015-09-23 2017-03-30 Uniwersytet Jagielloński Imidazopyridine compounds and their use as 5-ht6 receptor ligands
WO2017181317A1 (en) * 2016-04-18 2017-10-26 Eli Lilly And Company Treatment for nonalcoholic steatohepatitis and fibrosis
WO2017184412A1 (en) 2016-04-18 2017-10-26 Eli Lilly And Company Purine cannabinoid agonist for treating nonalcoholic steatohepatitis and fibrosis
WO2018137176A1 (en) * 2017-01-25 2018-08-02 Eli Lilly And Company Treatment for nonalcoholic steatohepatitis and fibrosis
US10696677B2 (en) * 2016-12-21 2020-06-30 Research Triangle Institute Diaryl purine derivatives with improved bioavailability
WO2018208848A1 (en) 2017-05-08 2018-11-15 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of visceral pain
WO2024017227A1 (zh) * 2022-07-21 2024-01-25 长春金赛药业有限责任公司 取代的稠环大麻素受体化合物及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001060835A1 (en) * 2000-02-18 2001-08-23 Pfizer Limited Purine derivatives
CN1708499A (zh) * 2002-10-28 2005-12-14 辉瑞产品公司 嘌呤化合物及其作为大麻素受体配体的用途
WO2007092213A2 (en) * 2006-02-02 2007-08-16 Millennium Pharmaceuticals, Inc. Inhibitors of e1 activating enzyme
CN101044143A (zh) * 2004-10-22 2007-09-26 辉瑞产品公司 制备嘌呤化合物的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60260579A (ja) * 1984-01-13 1985-12-23 Yoshitomi Pharmaceut Ind Ltd プリン誘導体
NZ225447A (en) 1987-07-20 1991-12-23 Merck & Co Inc Piperazinyl derivatives of purine and purine isosteres and pharmaceutical compositions
US5057517A (en) * 1987-07-20 1991-10-15 Merck & Co., Inc. Piperazinyl derivatives of purines and isosteres thereof as hypoglycemic agents
WO2003022214A2 (en) 2001-09-06 2003-03-20 Millennium Pharmaceuticals, Inc. Piperazine and homopiperazine compounds
US20030139427A1 (en) 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
US20040224962A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US20050043327A1 (en) * 2003-08-21 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
US20050187389A1 (en) 2004-01-13 2005-08-25 Ambit Biosciences Corporation Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
WO2006128172A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating b cell regulated autoimmune disorders
WO2011066211A1 (en) * 2009-11-24 2011-06-03 Glaxosmithkline Llc Azabenzimidazoles as fatty acid synthase inhibitors
AR080711A1 (es) * 2010-03-31 2012-05-02 Lilly Co Eli Compuesto de piperazin-purina composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento o prevencion del dolor

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001060835A1 (en) * 2000-02-18 2001-08-23 Pfizer Limited Purine derivatives
CN1708499A (zh) * 2002-10-28 2005-12-14 辉瑞产品公司 嘌呤化合物及其作为大麻素受体配体的用途
CN101044143A (zh) * 2004-10-22 2007-09-26 辉瑞产品公司 制备嘌呤化合物的方法
WO2007092213A2 (en) * 2006-02-02 2007-08-16 Millennium Pharmaceuticals, Inc. Inhibitors of e1 activating enzyme

Also Published As

Publication number Publication date
JP2012512873A (ja) 2012-06-07
EA018386B1 (ru) 2013-07-30
PE20110999A1 (es) 2012-01-16
AU2009335997B2 (en) 2012-05-10
CA2746740C (en) 2014-01-14
CR20110340A (es) 2011-09-16
EA201170832A1 (ru) 2011-12-30
DOP2011000196A (es) 2011-10-31
ES2536880T3 (es) 2015-05-29
AU2009335997A1 (en) 2011-06-23
MA32904B1 (fr) 2011-12-01
CN102256977A (zh) 2011-11-23
BRPI0923195A2 (pt) 2016-02-16
KR20110084459A (ko) 2011-07-22
WO2010080306A1 (en) 2010-07-15
MX2011006442A (es) 2011-07-19
US8252798B2 (en) 2012-08-28
KR101319630B1 (ko) 2013-10-17
TN2011000291A1 (en) 2012-12-17
IL213167A (en) 2013-11-28
IL213167A0 (en) 2011-07-31
SG172253A1 (en) 2011-07-28
AR075104A1 (es) 2011-03-09
CA2746740A1 (en) 2010-07-15
TWI376378B (en) 2012-11-11
HN2011001700A (es) 2013-05-06
JP5559812B2 (ja) 2014-07-23
TW201024296A (en) 2010-07-01
UA104010C2 (en) 2013-12-25
NZ593088A (en) 2012-12-21
CL2011001464A1 (es) 2012-01-20
ECSP11011151A (es) 2011-07-29
EP2379555B1 (en) 2015-02-25
US20100160288A1 (en) 2010-06-24
EP2379555A1 (en) 2011-10-26
CO6390101A2 (es) 2012-02-29
PA8851501A1 (es) 2010-07-27
ZA201103943B (en) 2012-11-28

Similar Documents

Publication Publication Date Title
CN102256977B (zh) 嘌呤化合物
CN102892761B (zh) 4-氨基嘧啶衍生物和它们作为腺苷a2a 受体拮抗剂
TW201602084A (zh) 纖維母細胞生長因子受體抑制劑
JPH09504520A (ja) １ｎ−アルキル−ｎ−アリールピリミジンアミンおよびその誘導体
CN103582642A (zh) Hsp90抑制剂
EP2552921B1 (en) Purine compounds
CN115867280B (zh) 用于抗癌的5-氨基-8-(4-吡啶基)-[1,2,4]三唑并[4,3-c]嘧啶-3-酮化合物
AU2011235290B2 (en) Purine compounds used as CB2 agonists
CA2716202A1 (en) Pyrrolo[2,3-d]pyrimidin-2-yl-amine derivatives as pkc-theta inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140416

Termination date: 20201209